Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BiomX Inc. (PHGE-UN)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.8900-0.0600 (-6.32%)
At close: 03:59PM EDT
0.8900 0.00 (0.00%)
After hours: 07:46PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.9500
Open0.8602
Bid0.8610 x 800
Ask0.8900 x 800
Day's Range0.8500 - 0.9500
52 Week Range0.8500 - 0.9500
Volume25,711
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)0.63
PE Ratio (TTM)N/A
EPS (TTM)-1.3110
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PHGE-UN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

      BRANFORD, Conn. & NESS ZIONA, Israel, August 07, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, to report second quarter 2022 financial results and provide business updates. To participate in the conference call,

    • Business Wire

      BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

      BRANFORD, Conn. & NESS ZIONA, Israel, August 04, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the publication of a scientific paper titled "Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation" in the journal, Cell. The research was conducted across several organizati

    • Business Wire

      BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

      BRANFORD, Conn. & NESS ZIONA, Israel, July 06, 2022--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced today that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange (the "TASE").

    Advertisement
    Advertisement